Earnings summaries and quarterly performance for LifeStance Health Group.
Executive leadership at LifeStance Health Group.
Board of directors at LifeStance Health Group.
Research analysts who have asked questions during LifeStance Health Group earnings calls.
Craig Hettenbach
Morgan Stanley
4 questions for LFST
Also covers: ACCD, AMWL, ARDT +10 more
Jamie Perse
The Goldman Sachs Group, Inc.
4 questions for LFST
Also covers: BTSG, CON, DOCS +8 more
Brian Tanquilut
Jefferies
3 questions for LFST
Also covers: ACHC, ADUS, AHCO +29 more
Kevin Caliendo
UBS
2 questions for LFST
Also covers: AHCO, ALGN, AMWL +15 more
Lisa Gill
JPMorgan Chase & Co.
2 questions for LFST
Also covers: AGL, CAH, CI +13 more
Richard Close
Canaccord Genuity Group
2 questions for LFST
Also covers: ACCD, AHCO, CLOV +15 more
Andrea Zayco Narvaez Alfonso
UBS
1 question for LFST
Also covers: ELAN, EVH, ZTS
David Larsen
BTIG
1 question for LFST
Also covers: ACCD, AGL, AMWL +19 more
Jack Senft
William Blair
1 question for LFST
Also covers: AMWL, HCSG, MD +3 more
Matthew Mardula
William Blair
1 question for LFST
Also covers: ASTH, HCSG, TALK +1 more
Ryan Daniels
William Blair & Company, L.L.C.
1 question for LFST
Also covers: ACCD, AGL, ALHC +12 more
Stephanie Davis
Barclays
1 question for LFST
Also covers: ACCD, CAH, COR +20 more
Steve Dechert
KeyBanc Capital Markets
1 question for LFST
Also covers: ABCL, ABSI, CERT +2 more
Recent press releases and 8-K filings for LFST.
LFST Reports Strong Q3 2025 Results, Raises Full-Year Adjusted EBITDA Guidance
LFST
Earnings
Guidance Update
Revenue Acceleration/Inflection
- LifeStance Health (LFST) reported strong third-quarter 2025 financial results, with revenue growing 16% year-over-year to $364 million and adjusted EBITDA increasing 31% year-over-year to $40 million, achieving an 11.1% margin which is the highest since going public. The company also achieved positive net income of $1.1 million.
- Operational performance was robust, marked by 17% year-over-year organic visit growth to 2.3 million visits, driven by a record 288 organic net clinician adds and a 5% increase in visits per average clinician.
- For the full year 2025, the company raised its adjusted EBITDA guidance midpoint by $4 million to $146-$152 million, while maintaining its revenue guidance midpoint of $1.41-$1.43 billion.
- Looking ahead to 2026, LifeStance anticipates mid-teens revenue growth driven by low double-digit visit volume increases and low to mid-single-digit rate improvements, with expectations for continued margin expansion and positive net income and earnings per share for the full year.
- The company plans to make additional investments in Q4 2025, which will result in a sequential decrease in Q4 margins, to better position itself for achieving its 2026 growth objectives.
Nov 6, 2025, 1:30 PM
LifeStance Health Reports Q3 2025 Financial Results
LFST
Earnings
Revenue Acceleration/Inflection
- LifeStance Health reported Total Revenue of $363.8 million for Q3 2025.
- The company achieved Adjusted EBITDA of $40.2 million with an 11.1% margin and a Net income of $1.1 million in Q3 2025.
- Center Margin for Q3 2025 was $116.6 million , representing a 32.0% margin.
- Clinician count reached 7,996 , supporting 2,299,000 Total Visits in Q3 2025.
- The company generated Free Cash Flow of $17.0 million and ended Q3 2025 with $203.9 million in cash and cash equivalents.
Nov 6, 2025, 1:30 PM
LifeStance Health Group Reports Strong Q3 2025 Results and Raises FY 2025 Adjusted EBITDA Outlook
LFST
Earnings
Guidance Update
Revenue Acceleration/Inflection
- LifeStance Health Group reported Q3 2025 revenue of $363.8 million, a 16% increase compared to the prior-year period, and achieved net income of $1.1 million.
- Adjusted EBITDA for Q3 2025 grew 31% to $40.2 million, supported by an 11% increase in its clinician base to 7,996 and a 17% rise in visit volumes to 2.3 million.
- The company generated $27.3 million in net cash provided by operations and $17.0 million in Free Cash Flow during Q3 2025, ending the quarter with a cash position of $203.9 million.
- For the full year 2025, LifeStance reiterated its revenue expectations of $1.41 billion to $1.43 billion and raised its Adjusted EBITDA expectations to $146 million to $152 million.
Nov 6, 2025, 11:00 AM
LifeStance Health Group, Inc. Reports Strong Q3 2025 Results and Raises Full-Year Adjusted EBITDA Guidance
LFST
Earnings
Guidance Update
Revenue Acceleration/Inflection
- LifeStance Health Group, Inc. reported revenue of $363.8 million for the third quarter ended September 30, 2025, marking a 16% increase compared to the prior year, and achieved net income of $1.1 million.
- Adjusted EBITDA increased 31% to $40.2 million in Q3 2025, with a Free Cash Flow of $17.0 million.
- The company's clinician base grew 11% to 7,996 clinicians, and visit volumes increased 17% to 2.3 million in the third quarter.
- For the full year 2025, LifeStance reiterated revenue expectations of $1.41 billion to $1.43 billion and raised Adjusted EBITDA expectations to $146 million to $152 million.
Nov 5, 2025, 11:41 PM
MeridianLink Acquired by Centerbridge Partners
LFST
M&A
Delisting/Listing Issues
New Projects/Investments
- Centerbridge Partners has completed its acquisition of MeridianLink, leading to MeridianLink becoming a private company and its common stock being delisted from the New York Stock Exchange.
- MeridianLink shareholders received $20.00 in cash for each share of common stock they owned.
- Silversmith Capital Partners made a minority investment in MeridianLink to support its continued growth and innovation.
Oct 24, 2025, 12:29 PM
LifeStance Health Group Inc. announces Q2 2025 results and raises full-year guidance
LFST
Earnings
Guidance Update
- LifeStance Health Group Inc. reported Q2 2025 revenue of $345.3 million, an 11% increase year-over-year.
- The company's Q2 2025 Adjusted EBITDA was $34.0 million, or 9.8% as a percentage of revenue.
- Total clinicians increased to 7,708 in Q2 2025, up 11% year-over-year, with 173 net clinician adds during the quarter.
- LifeStance ended Q2 2025 with a cash position of $188.9 million.
- For full-year 2025, the company raised its guidance for Center Margin to $441 - $465 million and Adjusted EBITDA to $140 - $150 million, while reaffirming revenue guidance of $1,400 - $1,440 million.
Aug 7, 2025, 12:30 PM
Lifeist's Mikra Forms Strategic Partnership with ASICS Runkeeper and Race Roster
LFST
New Projects/Investments
Revenue Acceleration/Inflection
- Lifeist Wellness Inc.'s wholly owned subsidiary, Mikra Cellular Sciences, signed a strategic partnership on May 26, 2025, with the ASICS Runkeeper app and Race Roster.
- This collaboration aims to engage athletes seeking mental clarity, focus, and endurance, with Mikra launching exclusive fitness Challenges within the Runkeeper app in June.
- The partnership is expected to accelerate customer acquisition and reduce traditional marketing costs by leveraging the established user bases of Runkeeper and Race Roster.
- The first event generated 39,000 new users and more than 7,500 entries, proving to be a highly cost-effective addition to Mikra's conversion strategy.
Jul 31, 2025, 11:35 AM
LifeStance Health Group Outlines Strategic Priorities at Global Healthcare Conference
LFST
CEO Change
CFO Change
Guidance Update
- Leadership transition was emphasized with the CEO shift from Ken to Dave and a new CFO appointment, ensuring seamless continuity and enhanced strategic oversight.
- Operational excellence and profitable growth remain top priorities, with investments in digital tools (e.g., patient check-in solution) and initiatives to optimize clinician scheduling and retention.
- Guidance updates include expectations for low to mid single-digit payer rate increases and margin expansion targets, with long-term EBITDA margin goals of 15-20%.
Jun 10, 2025, 4:41 PM
Quarterly earnings call transcripts for LifeStance Health Group.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more